Search

Your search keyword '"Hadaschik, B.A."' showing total 108 results
Start Over Author "Hadaschik, B.A."
108 results on '"Hadaschik, B.A."'

3. Robotic partial nephrectomy in patients with a solitary kidney – a multicenter analysis

Author

Katzendorn, O., primary, Faraj Tabrizi, P., additional, Schiefelbein, F., additional, Schoen, G., additional, Wiesinger, C., additional, Pfuner, J., additional, Ubrig, B., additional, Gloger, S., additional, Nuhn, P., additional, Eraky, A., additional, Wagner, C., additional, Ayanle, A., additional, Kesch, C., additional, Al-Nader, M., additional, Hadaschik, B.A., additional, Fuhrmann, C., additional, Kuczyk, M.A., additional, Siemer, S., additional, Stöckle, M., additional, Zeuschner, P., additional, and Harke, N.N., additional

Published
2024
Full Text
View/download PDF

4. Urinary fistulae after robotic partial nephrectomy – analysis of a multicenter database

Author

Fuhrmann, C., primary, Katzendorn, O., additional, Schiefelbein, F., additional, Schoen, G., additional, Wiesinger, C., additional, Pfuner, J., additional, Ubrig, B., additional, Gloger, S., additional, Nuhn, P., additional, Eraky, A., additional, Wagner, C., additional, Ayanle, A., additional, Kesch, C., additional, Al-Nader, M., additional, Hadaschik, B.A., additional, Kuczyk, M.A., additional, Faraj Tabrizi, P., additional, Siemer, S., additional, Stöckle, M., additional, Zeuschner, P., additional, and Harke, N.N., additional

Published
2024
Full Text
View/download PDF

7. Why do surgeons need to change their intraoperative plan? A multicentric analysis of conversions in 2459 robot-assisted partial nephrectomies

Author

Katzendorn, O., primary, Harke, N.N., additional, Schiefelbein, F., additional, Schoen, G., additional, Wiesinger, C., additional, Pfuner, J., additional, Ubrig, B., additional, Gloger, S., additional, Osmonov, D., additional, Eraky, A., additional, Wagner, C., additional, Ayanle, A., additional, Hadaschik, B.A., additional, Kesch, C., additional, Kuczyk, M.A., additional, Siemer, S., additional, Stöckle, M., additional, and Zeuschner, P., additional

Published
2023
Full Text
View/download PDF

8. Intravesikale Therapie nicht muskelinvasiver Blasentumoren mit onkolytischen Vesikular-Stomatitisviren

Author

Hadaschik, B.A., Zhang, K., So, A.I., Bell, J.C., Thüroff, J.W., Rennie, P.S., and Gleave, M.E.

Abstract

Zusammenfassung: Patienten mit Hochrisikoblasentumoren, die nicht auf eine BCG-Immuntherapie ansprechen, stellen eine therapeutische Herausforderung dar. Als Second-line-Therapie wird derzeit häufig eine Kombination aus BCG plus Interferon empfohlen. Da jedoch ein Großteil aggressiv wachsender Tumoren nicht sensibel auf Interferon reagiert, käme anstatt dessen der Einsatz onkolytischer Vesikular-Stomatitisviren (VSV) in Betracht, die speziell Interferon-refraktäre Tumorzellen angreifen. In vitro töteten sowohl Wildtyp-VSV als auch ein attenuierter Subtyp, der eine gesteigerte Tumorselektivität aufweist, bevorzugt aggressiv wachsende, Interferon-resistente Blasentumorzellen. Anschließende In-vivo-Versuche in einem von uns validierten orthotopen Mausmodell konnten die viel versprechende antikanzerogene Aktivität beider Viren nach intravesikaler Gabe eindrucksvoll bestätigen. Obwohl in diesem Modell immunkompromittierte Nacktmäuse verwendet werden, zeigte sich keine virale Toxizität. Zusammenfassend scheinen frühe klinische Studien zur intravesikalen Therapie mit VSV gerechtfertigt.

Published
2024
Full Text
View/download PDF

9. Change of plan – A multicentric analysis of conversions in robot-assisted partial nephrectomy

Author

Katzendorn, O., primary, Harke, N.N., additional, Schiefelbein, F., additional, Schoen, G., additional, Wiesinger, C., additional, Pfuner, J., additional, Ubrig, B., additional, Gloger, S., additional, Osmonov, D., additional, Eraky, A., additional, Witt, J.H., additional, Wagner, C., additional, Hadaschik, B.A., additional, Radtke, J.P., additional, Kuczyk, M.A., additional, Huusmann, S., additional, Siemer, S., additional, Stöckle, M., additional, and Zeuschner, P.., additional

Published
2022
Full Text
View/download PDF

10. 1759P Enfortumab vedotin in metastatic urothelial carcinoma: Retrospective multicentre patient cohort

Author

Darr, C., primary, Zschäbitz, S., additional, Niegisch, G., additional, Roghmann, F., additional, Ivanyi, P., additional, Zengerling, F., additional, Paffenholz, P., additional, Biernath, N., additional, Klee, M., additional, Klümper, N., additional, Tauber, R.L., additional, Hadaschik, B.A., additional, Hilser, T., additional, and Grünwald, V., additional

Published
2022
Full Text
View/download PDF

14. Robot-assisted partial nephrectomy for multiple renal tumors – a multicenter analysis

Author

Harke, N.N., primary, Schiefelbein, F., additional, Schneller, A., additional, Schoen, G., additional, Wiesinger, C.G., additional, Pfuner, J., additional, Falkensammer, E., additional, Gilbert, N., additional, Eraky, A., additional, Zimmermanns, V., additional, Paramythelli, I., additional, Hadaschik, B.A., additional, Radtke, J.P., additional, Darr, C., additional, Kriegmair, M.C., additional, Flintrop, M., additional, Wolters, M., additional, Faraj Tabrizi, P., additional, Kuczyk, M.A., additional, and Osmonov, D., additional

Published
2022
Full Text
View/download PDF

15. Risk of adverse outcomes after prostatectomy in patients diagnosed with IUSP <= 2 prostate cancer on MRI/TRUS fusion biopsy

Author

Kesch, C.V., primary, Pantea, V., additional, Soeterik, T., additional, Marquis, A., additional, La Bombarda, G., additional, Morlacco, A., additional, Barletta, F., additional, Preisser, F., additional, Zattoni, F., additional, Marra, G., additional, Van Den Bergh, R.C.N., additional, Radtke, J.P., additional, Hadaschik, B.A., additional, and Gandaglia, G., additional

Published
2022
Full Text
View/download PDF

17. 649TiP PRIMORDIUM: A randomized, international, trial-in-progress of adding apalutamide to radiotherapy and an LHRH agonist in high-risk patients with PSMA-PET-positive hormone-sensitive prostate cancer

Author

Hadaschik, B.A., primary, Fanti, S., additional, Ost, P., additional, Tunariu, N., additional, de Nunzio, C., additional, Antoni, L., additional, Lukac, M., additional, Martin, J., additional, Pissart, G., additional, Wapenaar, R., additional, and Mottet, N., additional

Published
2021
Full Text
View/download PDF

18. Detection of significant prostate cancer using target saturation in transperineal magnetic resonance imaging/transrectal ultrasonography–fusion biopsy: A prospective, randomized comparison to conventional target biopsy

Author

Saner, Y., primary, Wiesenfarth, M., additional, Tschirdewahn, S., additional, Püllen, L., additional, Bonekamp, D., additional, Krafft, U., additional, Kesch, C., additional, Darr, C., additional, Forsting, M., additional, Umutlu, L., additional, Hadaschik, B.A., additional, and Radtke, J.P., additional

Published
2021
Full Text
View/download PDF

19. Role of MRI for the detection of prostate cancer

Author

Wu, R.C., Lebastchi, A.H., Hadaschik, B.A., Emberton, M., Moore, C., Laguna, P., Futterer, J.J., George, A.K., Wu, R.C., Lebastchi, A.H., Hadaschik, B.A., Emberton, M., Moore, C., Laguna, P., Futterer, J.J., and George, A.K.

Abstract

Item does not contain fulltext, The use of multiparametric MRI has been hastened under expanding, novel indications for its use in the diagnostic and management pathway of men with prostate cancer. This has helped drive a large body of the literature describing its evolving role over the last decade. Despite this, prostate cancer remains the only solid organ malignancy routinely diagnosed with random sampling. Herein, we summarize the components of multiparametric MRI and interpretation, and present a critical review of the current literature supporting is use in prostate cancer detection, risk stratification, and management.

Published
2021

20. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer

Author

Fanti, S., Goffin, K., Hadaschik, B.A., Herrmann, K., Maurer, T., MacLennan, S., Oprea-Lager, D.E., Oyen, W.J.G., Rouviere, O., Mottet, N., Bjartell, A., Fanti, S., Goffin, K., Hadaschik, B.A., Herrmann, K., Maurer, T., MacLennan, S., Oprea-Lager, D.E., Oyen, W.J.G., Rouviere, O., Mottet, N., and Bjartell, A.

Abstract

Contains fulltext : 232886.pdf (Publisher’s version ) (Open Access), PURPOSE: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is used for (re)staging prostate cancer (PCa) and as a biomarker for evaluating response to therapy, but lacks established response criteria. A panel of PCa experts in nuclear medicine, radiology, and/or urology met on February 21, 2020, in Amsterdam, The Netherlands, to formulate criteria for PSMA PET/CT-based response in patients treated for metastatic PCa and optimal timing to use it. METHODS: Panelists received thematic topics and relevant literature prior to the meeting. Statements on how to interpret response and progression on therapy in PCa with PSMA PET/CT and when to use it were developed. Panelists voted anonymously on a nine-point scale, ranging from strongly disagree (1) to strongly agree (9). Median scores described agreement and consensus. RESULTS: PSMA PET/CT consensus statements concerned utility, best timing for performing, criteria for evaluation of response, patients who could benefit, and handling of radiolabeled PSMA PET tracers. Consensus was reached on all statements. PSMA PET/CT can be used before and after any local and systemic treatment in patients with metastatic disease to evaluate response to treatment. Ideally, PSMA PET/CT imaging criteria should categorize patients as responders, patients with stable disease, partial response, and complete response, or as non-responders. Specific clinical scenarios such as oligometastatic or polymetastatic disease deserve special consideration. CONCLUSIONS: Adoption of PSMA PET/CT should be supported by indication for appropriate use and precise criteria for interpretation. PSMA PET/CT criteria should categorize patients as responders or non-responders. Specific clinical scenarios deserve special consideration.

Published
2021

28. 221P Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN

Author

Uemura, H., primary, Lee, J.Y., additional, Oudard, S., additional, Hadaschik, B.A., additional, Saad, F., additional, Cella, D., additional, Basch, E., additional, Graff, J.N., additional, Dibaj, S., additional, Li, S., additional, Brookman-May, S.D., additional, De Porre, P., additional, Bevans, K., additional, Trudeau, J., additional, Smith, M.R., additional, and Small, E.J., additional

Published
2020
Full Text
View/download PDF

29. 632P Health-related quality of life (HRQoL) at final analysis of the SPARTAN study of apalutamide (APA) vs placebo (PBO) in patients (pts) with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving androgen deprivation therapy (ADT)

Author

Oudard, S., primary, Hadaschik, B.A., additional, Saad, F., additional, Cella, D., additional, Basch, E., additional, Mainwaring, P.N., additional, Graff, J.N., additional, Dibaj, S., additional, Li, S., additional, Brookman-May, S.D., additional, De Porre, P., additional, Trudeau, J.J., additional, Small, E.J., additional, and Smith, M.R., additional

Published
2020
Full Text
View/download PDF

32. A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer

Author

Visschere, P.J. De, Standaert, C., Futterer, J.J., Villeirs, G.M., Panebianco, V, Walz, J., Maurer, T., Hadaschik, B.A., Lecouvet, F.E., Giannarini, G., Fanti, S., Visschere, P.J. De, Standaert, C., Futterer, J.J., Villeirs, G.M., Panebianco, V, Walz, J., Maurer, T., Hadaschik, B.A., Lecouvet, F.E., Giannarini, G., and Fanti, S.

Abstract

Contains fulltext : 205490.pdf (publisher's version ) (Closed access), CONTEXT: In patients treated for prostate cancer, a rising serum prostate-specific antigen (PSA) level is a first sign of relapse, but imaging is needed to determine the localization of the recurrence, which may be local, in lymph nodes, and/or metastatic. With the increasing success rate of earlier salvage therapy, the diagnosis has become pertinent when the recurrent PSA level is still very low. OBJECTIVE: To systematically review the literature on the role of the existing imaging techniques in patients with early recurrent prostate cancer. EVIDENCE ACQUISITION: A systematic literature search across the MEDLINE and EMBASE databases was conducted in February 2018, searching for original studies reporting on imaging in a (sub)group of patients with recurrent PSA levels not higher than 5ng/ml. This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. The methodological quality of the studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool. EVIDENCE SYNTHESIS: A total of 98 studies were included in this systematic review, reporting on the role of transrectal ultrasonography (TRUS), computed tomography (CT), bone scintigraphy (BS), single-photon emission CT, multiparametric magnetic resonance imaging (mpMRI), whole-body MRI (wbMRI), and positron emission tomography (PET)-CT/MRI using 18F fluoro-deoxy-glucose, 11C choline, 18F (fluoro)(methyl)choline, 11C acetate, 18F FACBC (fluciclovine) and prostate-specific membrane antigen (PSMA)-based tracers. CT and BS were not sufficiently sensitive in the early recurrence setting. For the detection of local recurrence, TRUS or mpMRI can be used; however, at the lowest PSA levels, few data were available, only after radical prostatectomy, showing a wide range of positivity. TRUS or mpMRI need to be combined with (PET)-CT to assess distant disease, but new techniques such as wbMRI, PET-MRI, or PET-CT allow

Published
2019

34. Apalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Updated results from the phase III SPARTAN study

Author

Smith, M.R., primary, Saad, F., additional, Chowdhury, S., additional, Oudard, S., additional, Hadaschik, B.A., additional, Graff, J.N., additional, Olmos, D., additional, Mainwaring, P.N., additional, Lee, J.Y., additional, Uemura, H., additional, De Porre, P., additional, Smith, A., additional, Zhang, K., additional, Lopez-Gitlitz, A., additional, and Small, E.J., additional

Published
2019
Full Text
View/download PDF

35. Prostate-specific membrane antigen positron-emission tomography (PSMA-PET) in high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC) SPARTAN-like patients (pts) negative by conventional imaging

Author

Hadaschik, B.A., primary, Weber, M., additional, Iravani, A., additional, Hofman, M.S., additional, Calais, J., additional, Czernin, J., additional, Ilhan, H., additional, Saad, F., additional, Small, E.J., additional, Smith, M.R., additional, Perez, P.M., additional, Hope, T.A., additional, Rauscher, I., additional, Londhe, A., additional, Lopez-Gitlitz, A., additional, Cheng, S., additional, Maurer, T., additional, Herrmann, K., additional, Eiber, M., additional, and Fendler, W.P., additional

Published
2019
Full Text
View/download PDF

37. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

Author

Smith, M.R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B.A., Graff, J.N., Olmos, D., Mainwaring, P.N., Lee, J.Y., Uemura, H., Lopez-Gitlitz, A., Trudel, G.C., Espina, B.M., Shu, Y., Park, Y.C., Rackoff, W.R., Mulders, P.F.A., Yu, M.K., Small, E.J., Smith, M.R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B.A., Graff, J.N., Olmos, D., Mainwaring, P.N., Lee, J.Y., Uemura, H., Lopez-Gitlitz, A., Trudel, G.C., Espina, B.M., Shu, Y., Park, Y.C., Rackoff, W.R., Mulders, P.F.A., Yu, M.K., and Small, E.J.

Abstract

Contains fulltext : 193640.pdf (publisher's version ) (Open Access), BACKGROUND: Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer. We evaluated the efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer who were at high risk for the development of metastasis. METHODS: We conducted a double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic castration-resistant prostate cancer and a prostate-specific antigen doubling time of 10 months or less. Patients were randomly assigned, in a 2:1 ratio, to receive apalutamide (240 mg per day) or placebo. All the patients continued to receive androgen-deprivation therapy. The primary end point was metastasis-free survival, which was defined as the time from randomization to the first detection of distant metastasis on imaging or death. RESULTS: A total of 1207 men underwent randomization (806 to the apalutamide group and 401 to the placebo group). In the planned primary analysis, which was performed after 378 events had occurred, median metastasis-free survival was 40.5 months in the apalutamide group as compared with 16.2 months in the placebo group (hazard ratio for metastasis or death, 0.28; 95% confidence interval [CI], 0.23 to 0.35; P<0.001). Time to symptomatic progression was significantly longer with apalutamide than with placebo (hazard ratio, 0.45; 95% CI, 0.32 to 0.63; P<0.001). The rate of adverse events leading to discontinuation of the trial regimen was 10.6% in the apalutamide group and 7.0% in the placebo group. The following adverse events occurred at a higher rate with apalutamide than with placebo: rash (23.8% vs. 5.5%), hypothyroidism (8.1% vs. 2.0%), and fracture (11.7% vs. 6.5%). CONCLUSIONS: Among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo. (Funded by Janssen Research and Development; SPARTAN ClinicalTrials.gov n

Published
2018

38. Supplementary Material for: TOP: Prospective Evaluation of a Volume Based, Computer Assisted Method for Transperineal Optimized Prostate Biopsy

Author

Kesch, C., Radtke, J.P., Popeneciu, I.V., Gasch, C., Dieffenbacher, S.C., Klein, T., Schlemmer, H.-P., Wieczorek, K., Zogal, P., Hohenfellner, M., Sakas, G., and Hadaschik, B.A.

Abstract

Objective: This study is a prospective evaluation of a volume-based, computer-assisted method for transperineal optimized prostate (TOP) biopsy. The TOP algorithm automates core planning for systematic prostate biopsies using the 3-dimensional organ contour and an alterable volume for tumors to be excluded. Subjects and Methods: MRI-transrectal ultrasound fusion biopsy with MRI-targeted biopsies (TBs) and systematic-TOP biopsies were performed on 172 men between October 2013 and March 2014. Systematic biopsies were placed according to TOP for detection of tumor volumes >0.5 mL with a minimum of 80% organ coverage in prostates up to 50 mL (70% in larger organs). Results: Median 24 TOP cores and 3 MRI-TBs have been placed. Prostate cancer (PCa) was detected in 112 of 172 (65%) of men; TOP detected 109 (97%) and TB 62 (55%). Significant cancer (Gleason score ≥7) was detected in 75 (44%) of men and of these TOP detected 73 of 75 (97%) and TB 51 of 75 (68%). Overall, systematic-TOP sampling significantly outperformed TB for the detection of both, all PCa as well as significant PCa (p < 0.0001, p = 0.0005). Conclusion: The TOP method is innovative by integrating the individual prostate volume and PCa volume detection thresholds. In the present cohort, it diagnosed more significant tumors than TB alone. However, at the same time, more low-risk tumors are detected.

Published
2017
Full Text
View/download PDF

39. PCN37 - MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF APALUTAMIDE AND ENZALUTAMIDE IN THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Author

Chowdhury, S., primary, Oudard, S., additional, Hadaschik, B.A., additional, Uemura, H., additional, Joniau, S., additional, Pilon, D., additional, Ladouceur, M., additional, Behl, A., additional, Liu, J., additional, Dearden, L., additional, Sermon, J., additional, Van Sanden, S., additional, and Diels, J., additional

Published
2018
Full Text
View/download PDF

40. Health-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN: A phase III trial of apalutamide (APA) versus placebo (PBO) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC)

Author

Small, E.J., primary, Cella, D., additional, McQuarrie, K., additional, Saad, F., additional, Hadaschik, B.A., additional, Graff, J.N., additional, Uemura, H., additional, Oudard, S., additional, Yu, M.K., additional, Hudgens, S., additional, Lopez-Gitlitz, A., additional, Rooney, B., additional, Morris, M., additional, and Smith, M.R., additional

Published
2018
Full Text
View/download PDF

43. Prostate evaluation for clinically important disease: Sampling using image-guidance or not? (The PRECISION study, NCT02380027)

Author

Kasivisvanathan, V., primary, Rannikko, A.S., additional, Borghi, M., additional, Panebianco, V., additional, Mynderse, L.A., additional, Vaarala, M.H., additional, Briganti, A., additional, Budäus, L., additional, Hellawell, G., additional, Hindley, R.G., additional, Roobol, M.J., additional, Eggener, S., additional, Ghei, M., additional, Villers, A., additional, Bladou, F., additional, Villeirs, G.M., additional, Virdi, J., additional, Boxler, S., additional, Robert, G., additional, Singh, P.B., additional, Venderink, W., additional, Hadaschik, B.A., additional, Ruffion, A., additional, Hu, J., additional, Margolis, D., additional, Crouzet, S., additional, Klotz, L., additional, Taneja, S.S., additional, Pinto, P., additional, Gill, I., additional, Allen, C., additional, Giganti, F., additional, Freeman, A., additional, Morris, S., additional, Punwani, S., additional, Williams, N., additional, Brew-Graves, C., additional, Takwoingi, Y., additional, Emberton, M., additional, and Moore, C.M., additional

Published
2018
Full Text
View/download PDF

47. 523 - Prostate-specific membrane antigen positron-emission tomography (PSMA-PET) in high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC) SPARTAN-like patients (pts) negative by conventional imaging

Author

Hadaschik, B.A., Weber, M., Iravani, A., Hofman, M.S., Calais, J., Czernin, J., Ilhan, H., Saad, F., Small, E.J., Smith, M.R., Perez, P.M., Hope, T.A., Rauscher, I., Londhe, A., Lopez-Gitlitz, A., Cheng, S., Maurer, T., Herrmann, K., Eiber, M., and Fendler, W.P.

Published
2019
Full Text
View/download PDF

50. 1225 - Prostate evaluation for clinically important disease: Sampling using image-guidance or not? (The PRECISION study, NCT02380027)

Author

Kasivisvanathan, V., Rannikko, A.S., Borghi, M., Panebianco, V., Mynderse, L.A., Vaarala, M.H., Briganti, A., Budäus, L., Hellawell, G., Hindley, R.G., Roobol, M.J., Eggener, S., Ghei, M., Villers, A., Bladou, F., Villeirs, G.M., Virdi, J., Boxler, S., Robert, G., Singh, P.B., Venderink, W., Hadaschik, B.A., Ruffion, A., Hu, J., Margolis, D., Crouzet, S., Klotz, L., Taneja, S.S., Pinto, P., Gill, I., Allen, C., Giganti, F., Freeman, A., Morris, S., Punwani, S., Williams, N., Brew-Graves, C., Takwoingi, Y., Emberton, M., and Moore, C.M.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results